Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,112 people get ALXN articles and Market Currents by email alert.
Get email alerts on ALXN »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
Alexion To Power Higher Even Without Takeover BidSupreme Alpha • Thu, Aug 23, 2012 -
Alexion Pharmaceuticals: A Tricky Mix Of Biotech And PharmaStephen Simpson • Tue, Feb 14, 2012 -
-
-
-
Alexion Pharmaceuticals Bucking The Market's Downward TrendTed Stamas • Tue, Sep 13, 2011 -
Alexion Pharmaceuticals: Expanding Markets Point to Bigger ProfitsTodd Campbell • Wed, Apr 27, 2011
-
Alexion Pharmaceuticals: From Acquisition Target to AcquirerJason Chew • Mon, Feb 14, 2011 -
Alexion Pharma Has Plenty of Room to GrowJason Chew • Sun, Oct 24, 2010
-
-
Alexion Posts a Strong Quarter on Renewed SalesZacks Investment Research • Fri, Apr 23, 2010 -
Alexion: Hoping to Be Big in JapanZacks Investment Research • Mon, Apr 19, 2010
-
Alexion Pharma: Bounce Play?Notable Calls • Thu, Feb 21, 2008 -
Alexion Pharmaceuticals: Costs of Healthcare Rise to the ExtremeChad Brand • Fri, Mar 30, 2007 -
To learn more about Seeking Alpha Pro, click here.
-
-
-
Summer StocksBespoke Investment Group • Tue, Jun 11 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Alexion's CEO Discusses Q1 2012 Results - Earnings Call TranscriptTue, Apr 24, 2012
-
Alexion Pharmaceuticals Q4 2008 Earnings Call TranscriptThu, Feb 12, 2009
-
Alexion Pharmaceuticals Inc. Q3 2008 Earnings Conference Call TranscriptFri, Oct 24, 2008
-
Alexion Pharmaceuticals, Inc. Q2 2008 Earnings CallTue, Jul 29, 2008 • 1 Comment
-
Alexion Pharmaceuticals, Inc. Q1 2008 Earnings Call TranscriptWed, Apr 30, 2008
-
Alexion Pharmaceuticals, Inc. Q4 2007 Earnings Call TranscriptThu, Feb 14, 2008
-
at MarketWatch.com (Wed, 4:28PM)
-
Business Wire (Mon, 3:08PM)
-
Business Wire (Jun 12, 2013)
-
Business Wire (Jun 10, 2013)
-
Business Wire (Jun 5, 2013)
-
Business Wire (May 30, 2013)
-
Business Wire (May 23, 2013)
-
at MarketWatch.com (May 21, 2013)
-
at MarketWatch.com (May 10, 2013)
-
Business Wire (May 8, 2013)
-
at MarketWatch.com (Apr 25, 2013)
-
Business Wire (Apr 25, 2013)
-
Business Wire (Apr 25, 2013)
-
at MarketWatch.com (Apr 22, 2013)
-
Business Wire (Apr 11, 2013)
-
at CNBC.com (Apr 1, 2013)
-
at MarketWatch.com (Mar 28, 2013)
ALXN vs. ETF Alternatives
Company Description
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, June 6, 10:14 AM Alexion Pharmaceuticals (ALXN +1.8%) says data published on two of its trials in the June 6 issue of The New England Journal of Medicine demonstrates the efficacy of chronic Soliris therapy in the treatment of atypical hemolytic uremic syndrome, a rare, genetic disease associated with vital organ failure and premature death. Both trials also demonstrated positive results in secondary endpoints. Comment! [Healthcare, On the Move]
- Tuesday, May 28, 7:38 AM The FDA grants Alexion Pharmaceuticals' (ALXN) enzyme replacement therapy asfotase alfa Breakthrough Therapy Designation for the treatment of the metabolic disorder hypophosphatasia. On the most recent CC, management said the company "remains on track for a pediatric filing for asfotase alfa in the United States and Europe in 2014. Shares +2.23% premarket. (PR, transcript) Comment! [Healthcare]
- Thursday, May 16, 1:49 PM Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3%, ALXN -4.2%, VRTX -2.3%, CELG -4.5%, ARRY -2.2%, AMGN -1.4%. 1 Comment [Healthcare, On the Move]
- Thursday, April 25, 7:58 AM More on Alexion Pharmaceuticals' (ALXN) Q1: Shares up 3% premarket after top and bottom line beat as the company raises its FY2013 guidance. ALXN now sees EPS of between $2.87-2.97 on revenue of between $1.505-1.520B, up from previous guidance of $2.82-2.92 on sales of $1.49-1.505B. Analysts expect EPS of $2.90 on $1.51B in sales. (PR) Comment! [Healthcare, On the Move, Earnings]
- Thursday, April 25, 6:34 AM Alexion Pharma (ALXN): Q1 EPS of $0.65 beats by $0.05. Revenue of $338.9M (+38% Y/Y) beats by $2.34M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, April 25, 12:05 AM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
- Wednesday, April 24, 5:30 PM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
- Thursday, March 28, 11:09 AM Piper Jaffray says investors should consider buying Alexion Pharmaceuticals (ALXN -2.2%) on weakness stemming from an FDA warning letter. Analyst Ian Somaiya says the company likely will reach an agreement with the FDA regarding the manufacturing practices cited in the letter. ALXN says the issue will not cause supply disruptions. Comment! [Healthcare]
- Friday, February 15, 3:13 PM Alexion Pharmaceuticals (ALXN -1.8%) slips after Stifel Nicolaus cuts its price target on the shares from $125 to $118. The firm says that despite posting solid top and bottom line growth last year, the timing of European aHUS reimbursements and incremental data/news flow is mostly back-weighted to the second half. Comment! [Healthcare, On the Move]
- Thursday, February 14, 10:25 AM Shares of Alexion Pharmaceuticals (ALXN -2.3%) slip this morning, after ramping higher in pre-market trading on a solid Q4 earnings report that easily topped estimates but disappointed on revenue guidance. The company expects FY13 EPS in the range of $2.82 - $2.92, above the consensus of $2.77, but it projects revenue coming in just in line with the Street at $1.49B- $1.505B. The consensus Street view is for $1.49B. 4 Comments [Healthcare, Earnings, On the Move]
- Thursday, February 14, 6:31 AM Alexion Pharma (ALXN): Q4 EPS of $0.6 beats by $0.08. Revenue of $320.5M (+41% Y/Y) beats by $4.01M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, February 14, 12:05 AM Notable earnings before Thursday’s open: ABB, ABX, ALXN, ANR, APA, BGCP, BWA, CAB, CRIS, CVE, DISCA, DTV, DVA, DWRE, ECA, GELG, GM, GNC, GNRC, INCY, JAH, LNT, LUFK, MFA, NGLS, NRF, O, OAK, PDS, PEP, PPL, REGN, SHPG, STRA, TAP, UTHR, VMC, WM, ZIP Comment! [Earnings]
- Wednesday, February 13, 5:30 PM Notable earnings before Thursday’s open: ABB, ABX, ALXN, ANR, APA, BGCP, BWA, CAB, CRIS, CVE, DISCA, DTV, DVA, DWRE, ECA, GELG, GM, GNC, GNRC, INCY, JAH, LNT, LUFK, MFA, NGLS, NRF, O, OAK, PDS, PEP, PPL, REGN, SHPG, STRA, TAP, UTHR, VMC, WM, ZIP Comment! [Earnings]
-
Friday, December 7, 2012, 5:47 PM
After-hours top gainers, as of 5:15 p.m.: NXY +15%. PLCM +4%. AVGO +2%. UTIW +2%. ALXN +2%.
After-hours top losers: DMND -4%. TCK -3%. GRPN -3%. DOW -2%. BK -2%. 1 Comment [On the Move] - Friday, December 7, 2012, 12:33 PM Alexion Pharmaceuticals (ALXN -3.3%) dips after Citigroup intitiates coverage with a tepid Neutral rating, saying its current risk/reward profile isn't attractive. The firm notes that ALXN is presently trading at a very high P/E multiple that reflects optimistic expectations for upward EPS revisions. If history is a guide, the company will need to post significant upside surprises to offset the natural multiple contraction that is likely ahead. 1 Comment [Healthcare, On the Move]
- Thursday, November 8, 2012, 10:50 AM Alexion Pharmaceuticals (ALXN -1.2%) says its Board of Directors has authorized a $400M stock buyback. The Board's authorization is open-ended and doesn't establish a timeframe for the purchases, and the company expects to fund all repurchases from cash on hand and future cash flows from operations. 1 Comment [Healthcare]